SEC Form 4 · accession 0001209191-16-119284
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nessan Bermingham
Officer — President & CEO · Director
Period of report
May 11, 2016
Accepted (ET)
May 11, 2016 · 6:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001652130
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 11, 2016 | C | 437,019 | — | A | 786,633 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Founder StockF1,F2 | — | May 11, 2016 | C | 675,883 | D | — | — | Common Stock | 437,019 | 0 | D |
Explanation of responses
- F1Each share of Founder Stock was automatically converted into 0.6465903 of a share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.
- F2Not applicable